Study Design Type: Phase 2, double-blind, randomized, placebo-controlled study Participants: 338 adults (BMI 30 or BMI 27 with a coexisting condition) Groups: Retatrutide 1 mg, 4 mg, 8 mg, 12 mg (different initial doses 2 or 4 mg) and placebo Duration: 48 weeks (plus 4 weeks follow-up) Administration: subcutaneous, 1x weekly Primary endpoint: percentage change in body weight at week 24 Secondary endpoints: change in weight at week 48, 5%, 10%, 15% weight reduction
The same goes for certain types of autoimmune hypothyroidism or
Fewer implementation research projects that evaluate the strategies being used to implement or sustain study interventions The authors call for a shift from merely describing barriers and facilitators to evaluating the effectiveness of implementation strategies and their impact on meaningful outcomessuch as patient reach, provider adoption, and the sustainment of proven treatments for addiction
The fact that Eli Lilly has announced a significantly lower list price for Zepbound than Wegovy signals that they are not seeking to quietly avoid price competition, he added
What to Watch Out For 1